BR112019018648A2 - Inibidores de jak contendo uma amida heterocíclica com 4 membros - Google Patents

Inibidores de jak contendo uma amida heterocíclica com 4 membros Download PDF

Info

Publication number
BR112019018648A2
BR112019018648A2 BR112019018648-4A BR112019018648A BR112019018648A2 BR 112019018648 A2 BR112019018648 A2 BR 112019018648A2 BR 112019018648 A BR112019018648 A BR 112019018648A BR 112019018648 A2 BR112019018648 A2 BR 112019018648A2
Authority
BR
Brazil
Prior art keywords
compounds
starch
member heterocyclic
jak inhibitors
inhibitors containing
Prior art date
Application number
BR112019018648-4A
Other languages
English (en)
Inventor
R. Fatheree Paul
E.L. BRANDT Gary
Smith Cameron
D.E. Sullivan Steven
Jean Van Orden Lori
A. Kleinschek Melanie
D. CRATER Glenn
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of BR112019018648A2 publication Critical patent/BR112019018648A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a invenção fornece compostos de fórmula (i): (i) que contém uma amida heterocíclica de quatro membros onde as variáveis estão definidas na especificação, ou um sal aceitável do ponto de vista farmacêutico, portanto, que são inibidores de jak quinases. a invenção também fornece composições farmacêuticas que incluem tais compostos, métodos de uso de tais compostos para tratar doenças respiratórias e processos e intermediários úteis para preparar tais compostos.
BR112019018648-4A 2017-03-09 2018-03-08 Inibidores de jak contendo uma amida heterocíclica com 4 membros BR112019018648A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
US62/469,073 2017-03-09
PCT/US2018/021489 WO2018165392A1 (en) 2017-03-09 2018-03-08 Jak inhibitors containing a 4-membered heterocyclic amide

Publications (1)

Publication Number Publication Date
BR112019018648A2 true BR112019018648A2 (pt) 2020-06-16

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112019018649A BR112019018649A2 (pt) 2017-03-09 2018-03-08 inibidores jak derivados da fusão de imidazopiperidina
BR112019018648-4A BR112019018648A2 (pt) 2017-03-09 2018-03-08 Inibidores de jak contendo uma amida heterocíclica com 4 membros

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112019018649A BR112019018649A2 (pt) 2017-03-09 2018-03-08 inibidores jak derivados da fusão de imidazopiperidina

Country Status (20)

Country Link
US (10) US10196393B2 (pt)
EP (2) EP3592742B1 (pt)
JP (2) JP7134990B2 (pt)
KR (2) KR102526764B1 (pt)
CN (2) CN110382498B (pt)
AR (2) AR111241A1 (pt)
AU (2) AU2018231032B2 (pt)
BR (2) BR112019018649A2 (pt)
CA (1) CA2997772A1 (pt)
DK (1) DK3592742T3 (pt)
EA (2) EA037748B1 (pt)
ES (1) ES2882186T3 (pt)
IL (2) IL268689B2 (pt)
MX (2) MX2019010541A (pt)
PH (2) PH12019501941A1 (pt)
PT (1) PT3592742T (pt)
SG (2) SG11201907840RA (pt)
TW (2) TWI754019B (pt)
WO (2) WO2018165392A1 (pt)
ZA (2) ZA201905585B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3371185T (pt) * 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
NZ741737A (en) 2015-11-03 2023-11-24 Theravance Biopharma R&D Ip Llc Jak kinase inhibitor compounds for treatment of respiratory disease
AR111241A1 (es) 2017-03-09 2019-06-19 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR102568333B1 (ko) 2017-05-01 2023-08-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물을 사용하는 치료 방법
MA53229A (fr) * 2018-09-04 2022-05-11 Theravance Biopharma R&D Ip Llc Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
AU2019335199A1 (en) 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
WO2020092019A1 (en) * 2018-10-29 2020-05-07 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane compound as jak inhibitor
PE20212069A1 (es) * 2019-02-25 2021-10-26 Henan Medinno Pharmaceutical Tech Co Ltd Compuesto inhibidor de jak y uso del mismo
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
WO2021108803A1 (en) * 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
WO2021136345A1 (zh) * 2019-12-30 2021-07-08 路良 Jak抑制剂化合物及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) * 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
US20240092758A1 (en) * 2021-06-25 2024-03-21 Theravance Biopharma R&D Ip, Llc Imidazolo indazole compounds as jak inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
PT3001903T (pt) 2009-12-21 2017-12-18 Samumed Llc 1h-pirazolo[3,4-b]piridinas e usos terapêuticos destas
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
WO2013060636A1 (en) 2011-10-25 2013-05-02 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MY187446A (en) 2013-12-05 2021-09-22 Pfizer Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
AP2016009562A0 (en) 2014-05-14 2016-11-30 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3371184A1 (en) 2015-11-03 2018-09-12 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
NZ741737A (en) 2015-11-03 2023-11-24 Theravance Biopharma R&D Ip Llc Jak kinase inhibitor compounds for treatment of respiratory disease
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
AR111241A1 (es) 2017-03-09 2019-06-19 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR102568333B1 (ko) 2017-05-01 2023-08-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물을 사용하는 치료 방법
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
MA53229A (fr) 2018-09-04 2022-05-11 Theravance Biopharma R&D Ip Llc Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak
AU2019335199A1 (en) 2018-09-04 2021-03-11 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Also Published As

Publication number Publication date
EP3592743A1 (en) 2020-01-15
US20190127371A1 (en) 2019-05-02
PH12019501985A1 (en) 2020-10-05
BR112019018649A2 (pt) 2020-04-07
US11453668B2 (en) 2022-09-27
KR20190127796A (ko) 2019-11-13
CN110382498B (zh) 2022-07-12
US20180258088A1 (en) 2018-09-13
US10519153B2 (en) 2019-12-31
US10954237B2 (en) 2021-03-23
EA201992128A1 (ru) 2020-01-29
IL268689B2 (en) 2023-02-01
DK3592742T3 (da) 2021-08-09
US20190119275A1 (en) 2019-04-25
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
TW201837037A (zh) 2018-10-16
US10208040B2 (en) 2019-02-19
US10550118B2 (en) 2020-02-04
US11254669B2 (en) 2022-02-22
JP6974487B2 (ja) 2021-12-01
CN110382498A (zh) 2019-10-25
AU2018231035B2 (en) 2021-09-09
AU2018231032A8 (en) 2019-10-17
US11878977B2 (en) 2024-01-23
JP2020510015A (ja) 2020-04-02
CN110461839A (zh) 2019-11-15
US10196393B2 (en) 2019-02-05
MX2019010539A (es) 2019-10-21
IL268679B (en) 2021-10-31
SG11201907544VA (en) 2019-09-27
EA037748B1 (ru) 2021-05-18
AR111241A1 (es) 2019-06-19
IL268689A (en) 2019-10-31
US10392386B2 (en) 2019-08-27
ZA201905585B (en) 2020-05-27
PT3592742T (pt) 2021-07-30
US11667637B2 (en) 2023-06-06
US20210269436A1 (en) 2021-09-02
JP2020510010A (ja) 2020-04-02
IL268679A (en) 2019-10-31
US20220289737A1 (en) 2022-09-15
US20230063643A1 (en) 2023-03-02
US20200216447A1 (en) 2020-07-09
TWI779016B (zh) 2022-10-01
ES2882186T3 (es) 2021-12-01
NZ756823A (en) 2021-04-30
SG11201907840RA (en) 2019-09-27
ZA201905618B (en) 2021-05-26
US20180258087A1 (en) 2018-09-13
KR102533646B1 (ko) 2023-05-17
KR20190127798A (ko) 2019-11-13
US20200181141A1 (en) 2020-06-11
EA201992126A1 (ru) 2020-02-05
WO2018165395A1 (en) 2018-09-13
EP3592742A1 (en) 2020-01-15
AU2018231032B2 (en) 2021-08-19
CA2997772A1 (en) 2018-09-09
AR111242A1 (es) 2019-06-19
TW201840560A (zh) 2018-11-16
CN110461839B (zh) 2022-08-23
AU2018231035A1 (en) 2019-09-05
IL268689B (en) 2022-10-01
EA037261B1 (ru) 2021-03-01
AU2018231032A1 (en) 2019-09-05
JP7134990B2 (ja) 2022-09-12
EP3592742B1 (en) 2021-05-19
MX2019010541A (es) 2019-10-21
WO2018165392A1 (en) 2018-09-13
TWI754019B (zh) 2022-02-01
KR102526764B1 (ko) 2023-04-27

Similar Documents

Publication Publication Date Title
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112018072168A2 (pt) compostos derivados da pirimidina como inibidores da quinase jak
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
CR20200263A (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
BR112018015191A2 (pt) compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.
MX2019014438A (es) Derivados de acidos carboxilicos eficaces como inhibidores de la proteina quinasa.
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]